{
    "clinical_study": {
        "@rank": "46912", 
        "arm_group": [
            {
                "arm_group_label": "Loion", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "SA-Gel", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The study will be conducted to evaluate the efficacy and safety of a topical dimeticone\n      formulation (Loion\u00ae) compared to 10% salicylic acid in octyl-dodecanol with 15%\n      Macrogol-4-laurylether for the removal of scaling in patients with chronic psoriasis capitis\n      (scalp psoriasis)."
        }, 
        "brief_title": "Parallel Group Trial to Evaluate the Efficacy and Safety of Loion\u00ae Compared to 10% Salicylic Acid in Patients With Chronic Psoriasis Capitis", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": "Scalp Psoriasis", 
        "condition_browse": {
            "mesh_term": "Psoriasis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients \u2265 18 years of age\n\n          -  Having a diagnosis of chronic psoriasis capitis (scalp psoriasis) with or without the\n             involvement of other body areas and with or without psoriatic arthritis.\n\n          -  PSSI \u22655 (range 0-72)\n\n          -  Scaling \u22652 (on an scale from 0 to 4)\n\n          -  At least 10% of scalp area affected\n\n          -  If a women:\n\n          -  Postmenopausal\n\n          -  Premenopausal and using an established oral, injected or implanted hormonal method of\n             contraception, intrauterine device (IUD) or      intrauterine system (IUS)\n\n          -  Negative pregnancy test at inclusion\n\n          -  Patients with no concomitant systemic psoriasis medication.\n\n          -  Willingness and adherence to the prohibitions and restrictions specified in the study\n             protocol.\n\n          -  Willingness to self-administer the drug.\n\n          -  Signed informed consent document indicating that the patient to be included\n             understands the purpose of and the procedures for the study and is willing to\n             participate.\n\n        Exclusion Criteria:\n\n          -  Patients having a solely non- plaque form of psoriasis (e.g. erythrodermic, guttate,\n             pustular).\n\n          -  Patients with uncontrolled psoriasis under the current treatment.\n\n          -  Patients having received topical keratolytic agents for the scalp within the past 2\n             weeks and topical steroids for the scalp within the past week (prior to inclusion).\n\n          -  Patients receiving systemic antipsoriatic drugs, immunosuppressants or systemic\n             corticosteroids (within 4 weeks prior to inclusion).\n\n          -  Women who are pregnant or breastfeeding or planning to become pregnant during the\n             observational period.\n\n          -  Patients participating in another study using an investigational agent or procedure\n             during participation in the study observation period.\n\n          -  Known hypersensitivity to any ingredient in the investigational products'\n             formulations.\n\n          -  Having any condition that in the opinion of the investigator makes the participation\n             not be in the best interest of the subject.\n\n          -  Employees and staff of the investigator or study site with direct involvement in the\n             study as well as family members of the employee or the investigator."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01914627", 
            "org_study_id": "0741/179"
        }, 
        "intervention": [
            {
                "arm_group_label": "Loion", 
                "description": "The treatment will be carried out once daily (in the evening) onto all scaling areas of the scalp over a period of 2 weeks, with the last application of investigational products being applied one day prior to the final visit.", 
                "intervention_name": "Dimethicone", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "SA-Gel", 
                "description": "The treatment will be carried out once daily (in the evening) onto all scaling areas of the scalp over a period of 2 weeks, with the last application of investigational products being applied one day prior to the final visit.", 
                "intervention_name": "Salicylic Acid", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Salicylic Acid", 
                "Salicylates"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Psoriasis capitis", 
            "Scaling", 
            "Salicylic acid", 
            "Dimethicone", 
            "Plaque removal"
        ], 
        "lastchanged_date": "February 27, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Hamburg", 
                    "country": "Germany", 
                    "zip": "20246"
                }, 
                "name": "University Medical Center Hamburg-Eppendorf (UKE)"
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Single-centre Randomised, Active-controlled, Observer-blinded, Parallel Group Trial to Evaluate the Efficacy and Safety of a Topical Dimeticone Formulation (Loion\u00ae) Compared to 10% Salicylic Acid in the Removal of Scaling in Patients With Chronic Psoriasis Capitis", 
        "other_outcome": [
            {
                "description": "To evaluate clinical outcome of patients exposed to Loion or standard therapy for psoriasis capitis", 
                "measure": "Psoriasis Area Severity Index (PASI)", 
                "safety_issue": "No", 
                "time_frame": "at Day 0, day 3, day 7, day 14"
            }, 
            {
                "description": "To evaluate clinical outcome of patients exposed to Loion or standard therapy for psoriasis capitis", 
                "measure": "Body Surface Area (BSA)", 
                "safety_issue": "No", 
                "time_frame": "at Day 0, day 3, day 7, day 14"
            }, 
            {
                "description": "To evaluate global severity of skin of patients exposed to Loion or standard therapy for psoriasis capitis", 
                "measure": "Physician Global Assessment (PGA)", 
                "safety_issue": "No", 
                "time_frame": "at Day 0, day 3, day 7, day 14"
            }, 
            {
                "description": "To evaluate global severity of scalp skin of patients exposed to Loion or standard therapy for psoriasis capitis", 
                "measure": "Scalp Physician Global Assessment (sPGA)", 
                "safety_issue": "No", 
                "time_frame": "at Day 0, day 3, day 7, day 14"
            }, 
            {
                "description": "To evaluate disease related quality of life of patients exposed to Loion or standard therapy for psoriasis capitis", 
                "measure": "Dermatology Life Quality Index (DLQI)", 
                "safety_issue": "No", 
                "time_frame": "at Day 0, day 3, day 7, day 14"
            }, 
            {
                "description": "To evaluate the patient benefit of Loion or standard therapy for psoriasis capitis", 
                "measure": "Patient Benefit Index (PBI)", 
                "safety_issue": "No", 
                "time_frame": "at Day 0, day 3, day 7, day 14"
            }, 
            {
                "description": "To evaluate general state of health of patients exposed to Loion or standard therapy for psoriasis capitis", 
                "measure": "EuroQol Questionnaire (EQ-5D)", 
                "safety_issue": "No", 
                "time_frame": "at Day 0, day 3, day 7, day 14"
            }, 
            {
                "description": "Risk for adverse events and serious adverse events for patients exposed to Loion or standard therapy for psoriasis capitis", 
                "measure": "Adverse and serious adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "14 days"
            }
        ], 
        "overall_official": {
            "affiliation": "University Medical Center Hamburg-Eppendorf (UKE)", 
            "last_name": "Matthias Augustin, Prof.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "To evaluate improvement of scaling of patients exposed to Loion or standard therapy for psoriasis capitis", 
            "measure": "Change from Baseline in Scaling at 14 days", 
            "safety_issue": "No", 
            "time_frame": "14 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01914627"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "To evaluate clinical outcome of patients exposed to Loion or standard therapy for psoriasis capitis", 
            "measure": "Psoriasis Scalp Severity Index (PSSI)", 
            "safety_issue": "No", 
            "time_frame": "at Day 0, day 3, day 7, day 14"
        }, 
        "source": "G. Pohl-Boskamp GmbH & Co. KG", 
        "sponsors": {
            "collaborator": {
                "agency": "Universit\u00e4tsklinikum Hamburg-Eppendorf", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "G. Pohl-Boskamp GmbH & Co. KG", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}